The Ogilvie Lab

Medulloblastoma is the most common malignant pediatric brain tumor, yet its developmental origins and molecular drivers remain elusive. Current classification systems fail to capture the full biological complexity of the disease. Our lab is uncovering the fundamental mechanisms of tumor initiation, leveraging developmental biology, cell biology and bioinformatics to define the mechanisms governing medulloblastoma development and progression.

Despite aggressive treatment, many children with medulloblastoma relapse or suffer long-term side effects, and current therapies are not tailored to tumor biology. There is a critical need for targeted, less toxic strategies. Our lab is translating molecular discoveries into precision therapies, targeting vulnerabilities like splicing and protein synthesis pathways to drive the next generation of clinical interventions.